Discovery of selective ACAT2 antagonist via a combination strategy based on deep docking, pharmacophore modelling, and molecular dynamics simulation
Acyl-CoA: cholesterol acyltransferase (ACAT), a pivotal enzyme in the absorption and metabolism of cholesterol, is primarily responsible for intracellular esterification. ACAT inhibition is expected to diminish plasma lipid levels by impeding intestinal cholesterol absorption, thereby preventing the...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Journal of Enzyme Inhibition and Medicinal Chemistry |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/14756366.2024.2403736 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850252013534707712 |
|---|---|
| author | Yanfeng Liu Feng Ding Liangying Deng Shuran Zhang Lixing Wu Huangjin Tong |
| author_facet | Yanfeng Liu Feng Ding Liangying Deng Shuran Zhang Lixing Wu Huangjin Tong |
| author_sort | Yanfeng Liu |
| collection | DOAJ |
| description | Acyl-CoA: cholesterol acyltransferase (ACAT), a pivotal enzyme in the absorption and metabolism of cholesterol, is primarily responsible for intracellular esterification. ACAT inhibition is expected to diminish plasma lipid levels by impeding intestinal cholesterol absorption, thereby preventing the progression of atherosclerotic lesions. A previous study shows that selective inhibition of ACAT2 significantly mitigated hypercholesterolaemia and atherosclerosis in mouse models. Therefore, the need for ACAT2 selective inhibitors becomes particularly urgent. In this study, we established a multilayer virtual screening workflow and subjected biologically evaluated representative compounds to enzyme inhibitory assays. The experimental results indicated that the two compounds, STL565001 (inhibition rate at 25 μM: 75.7 ± 27.8%, selectivity = 6) and STL528213 (inhibition rate at 25 μM: 87.8 ± 12.4%, selectivity = 13), demonstrated robust activity against ACAT2, displaying greater selectivity for ACAT2 than for ACAT1. The molecular mechanisms governing the inhibitory activities of the selected compounds were systematically elucidated using computational approaches. In addition, hotspot residues in ACAT2 that are crucial for ligand binding were successfully identified. In summary, we devised a multilayer screening scheme to expeditiously and efficiently identify compounds with enzyme inhibitory activity, offering novel scaffolds for subsequent drug design centred on ACAT2 targets. |
| format | Article |
| id | doaj-art-c8ff3115c3e84120ab07080ebc6a6779 |
| institution | OA Journals |
| issn | 1475-6366 1475-6374 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Enzyme Inhibition and Medicinal Chemistry |
| spelling | doaj-art-c8ff3115c3e84120ab07080ebc6a67792025-08-20T01:57:45ZengTaylor & Francis GroupJournal of Enzyme Inhibition and Medicinal Chemistry1475-63661475-63742024-12-0139110.1080/14756366.2024.2403736Discovery of selective ACAT2 antagonist via a combination strategy based on deep docking, pharmacophore modelling, and molecular dynamics simulationYanfeng Liu0Feng Ding1Liangying Deng2Shuran Zhang3Lixing Wu4Huangjin Tong5Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, ChinaSchool of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, ChinaAffiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, ChinaAffiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, ChinaAffiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, ChinaAffiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, ChinaAcyl-CoA: cholesterol acyltransferase (ACAT), a pivotal enzyme in the absorption and metabolism of cholesterol, is primarily responsible for intracellular esterification. ACAT inhibition is expected to diminish plasma lipid levels by impeding intestinal cholesterol absorption, thereby preventing the progression of atherosclerotic lesions. A previous study shows that selective inhibition of ACAT2 significantly mitigated hypercholesterolaemia and atherosclerosis in mouse models. Therefore, the need for ACAT2 selective inhibitors becomes particularly urgent. In this study, we established a multilayer virtual screening workflow and subjected biologically evaluated representative compounds to enzyme inhibitory assays. The experimental results indicated that the two compounds, STL565001 (inhibition rate at 25 μM: 75.7 ± 27.8%, selectivity = 6) and STL528213 (inhibition rate at 25 μM: 87.8 ± 12.4%, selectivity = 13), demonstrated robust activity against ACAT2, displaying greater selectivity for ACAT2 than for ACAT1. The molecular mechanisms governing the inhibitory activities of the selected compounds were systematically elucidated using computational approaches. In addition, hotspot residues in ACAT2 that are crucial for ligand binding were successfully identified. In summary, we devised a multilayer screening scheme to expeditiously and efficiently identify compounds with enzyme inhibitory activity, offering novel scaffolds for subsequent drug design centred on ACAT2 targets.https://www.tandfonline.com/doi/10.1080/14756366.2024.2403736acyl-CoA: cholesterol acyltransferaseselective inhibitorsdeep dockingpharmacophore modellingmolecular dynamics simulation |
| spellingShingle | Yanfeng Liu Feng Ding Liangying Deng Shuran Zhang Lixing Wu Huangjin Tong Discovery of selective ACAT2 antagonist via a combination strategy based on deep docking, pharmacophore modelling, and molecular dynamics simulation Journal of Enzyme Inhibition and Medicinal Chemistry acyl-CoA: cholesterol acyltransferase selective inhibitors deep docking pharmacophore modelling molecular dynamics simulation |
| title | Discovery of selective ACAT2 antagonist via a combination strategy based on deep docking, pharmacophore modelling, and molecular dynamics simulation |
| title_full | Discovery of selective ACAT2 antagonist via a combination strategy based on deep docking, pharmacophore modelling, and molecular dynamics simulation |
| title_fullStr | Discovery of selective ACAT2 antagonist via a combination strategy based on deep docking, pharmacophore modelling, and molecular dynamics simulation |
| title_full_unstemmed | Discovery of selective ACAT2 antagonist via a combination strategy based on deep docking, pharmacophore modelling, and molecular dynamics simulation |
| title_short | Discovery of selective ACAT2 antagonist via a combination strategy based on deep docking, pharmacophore modelling, and molecular dynamics simulation |
| title_sort | discovery of selective acat2 antagonist via a combination strategy based on deep docking pharmacophore modelling and molecular dynamics simulation |
| topic | acyl-CoA: cholesterol acyltransferase selective inhibitors deep docking pharmacophore modelling molecular dynamics simulation |
| url | https://www.tandfonline.com/doi/10.1080/14756366.2024.2403736 |
| work_keys_str_mv | AT yanfengliu discoveryofselectiveacat2antagonistviaacombinationstrategybasedondeepdockingpharmacophoremodellingandmoleculardynamicssimulation AT fengding discoveryofselectiveacat2antagonistviaacombinationstrategybasedondeepdockingpharmacophoremodellingandmoleculardynamicssimulation AT liangyingdeng discoveryofselectiveacat2antagonistviaacombinationstrategybasedondeepdockingpharmacophoremodellingandmoleculardynamicssimulation AT shuranzhang discoveryofselectiveacat2antagonistviaacombinationstrategybasedondeepdockingpharmacophoremodellingandmoleculardynamicssimulation AT lixingwu discoveryofselectiveacat2antagonistviaacombinationstrategybasedondeepdockingpharmacophoremodellingandmoleculardynamicssimulation AT huangjintong discoveryofselectiveacat2antagonistviaacombinationstrategybasedondeepdockingpharmacophoremodellingandmoleculardynamicssimulation |